Marizomib

This research study is evaluating the safety, tolerability and preliminary efficacy of the drugs marizomib and panobinostat in pediatric patients with diffuse intrinsic pontine glioma (DIPG).
The names of the study drugs involved in this study are:
Marizomib
Panobinostat

Background:
Ependymomas are rare tumors that arise from the ependyma. That is a tissue of the central nervous system. They can develop in the brain or the spine. They are usually treated with surgery, radiation, and/or chemotherapy. Researchers want to see if the new drug marizomib can help people with a certain kind of ependymoma.
Objective:
To see if marizomib stops tumor growth and prolongs the time that the tumor is controlled.
Eligibility:
Adults age 18 and older who have been diagnosed with ependymomas and have already been treated with standard therapies
Design:
Participants will be screened with the following tests or recent results from similar tests:
Medical history
Physical exam
Neurological assessment
Electrocardiogram (EKG) to evaluate the heart
Review of symptoms and ability to perform normal activities
Computed tomographic scan (CT) or magnetic resonance imaging (MRI) to produce an image of the brain or spine.
Blood and urine tests
Tests of tumor samples. Participants may have to have new tumor samples taken.
Participants will get the study drug in cycles. Each cycle is 4 weeks. Participants will have up to 24 cycles.
Participants will get the study drug through a small plastic tube in a vein on days 1, 8, and 15 of each cycle.
During each cycle, some screening tests will be repeated.
Participants will answer questions about their general well-being and functioning.
About 4 5 weeks after finishing the study drug, participants will have a follow-up visit. They will answer questions about their health, get a physical and a neurological exam, and have blood tests. They may have an MRI or CT scan.
...